Trials / Active Not Recruiting
Active Not RecruitingNCT04629729
FT819 in Subjects With B-cell Malignancies
A Phase I Study of FT819 in Subjects With B-cell Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Fate Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FT819 | Experimental Interventional Therapy |
| DRUG | Cyclophosphamide | Lympho-conditioning agent |
| DRUG | Fludarabine | Lympho-conditioning agent |
| DRUG | IL-2 | Biologic response modifier |
| DRUG | Bendamustine | Lympho-conditioning agent |
Timeline
- Start date
- 2021-07-12
- Primary completion
- 2025-06-18
- Completion
- 2039-09-30
- First posted
- 2020-11-16
- Last updated
- 2026-03-19
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04629729. Inclusion in this directory is not an endorsement.